Skip to main content

NCBiotech News

  • Companies and university researchers across North Carolina are harnessing compounds, microorganisms and unique materials to bring advanced wound healing, surgical devices and regenerative medicine to civilian and military markets.
  • North Carolina is one of the world’s leading centers for the manufacture of biologics, pharmaceuticals, vaccines, diagnostics, medical devices and related products.
  • A study of the state’s life science landscape by the Battelle lists crop genetic engineering as one of six emerging life science technology sectors likely to flourish into the future. The  Technology Partnership Practice
  • North Carolina’s life science sector grew four times faster than that of the rest of the nation over the last decade. Even so, a study of the state’s industry says the best is yet to come, as the state builds on its “SuperSciNCe” – its prodigious research and innovation strengths in such growing markets as medicine, agriculture, biomanufacturing and health informatics.
  • Funding and other support from the North Carolina Biotechnology Center helped lay important groundwork for a possible $1.2 billion influx from Vertex Pharmaceuticals to Durham cystic fibrosis drug developer Parion Sciences.
  • Durham-based Viamet Pharmaceuticals has won a $1.95 million grant from the Department of Defense to develop a topical antifungal agent for preventing and treating mold infections in soldiers with battlefield wounds.
  • Morrisville medical imaging company Bioptigen, a 2004 Duke University spinout which makes specialized high-resolution imaging devices for non-invasive diagnoses of eye diseases and other medical applications, has reached agreement to be purchased by German powerhouse Leica Microsystems.
  •  A genetic testing laboratory recruited to the state in 2011 with help from the North Carolina Biotechnology Center is about to expand.
  • Modern agriculture has come a long way since the days when farming was basically “fert ‘n’ dirt.” That became clear as 135 movers and shakers from the expanding world of agricultural biotechnology shared ideas, auditions and a jam-packed day at NCBiotech’s third annual Ag Biotech Entrepreneurial Showcase.
  • Only two months ago, the FDA issued a coveted fast track designation for an immune therapy being developed by Durham's Heat Biologics. It's code named HS-410 (Vesigenurtacel L), targeting bladder cancer. Now the company is starting a new phase one-b trial of its other lead product, Viagenpumatucel-L (HS-110) to treat non-small cell lung cancer.
  •  
  • The North Carolina Biotechnology Center’s inaugural Southeast Investor & Venture Philanthropy Oncology Summit drew 126 of the region's cancer fighters together to showcase the National Cancer Institute, a variety of oncology venture philanthropists, and more than 30 of the region’s top private oncology companies.
  • A $50,000 startup loan from the North Carolina Biotechnology Center has helped a young Chapel Hill pharmaceutical developer, Spyryx Biosciences, secure an $18 million Series A investment from a venture capital syndicate.
  • The North Carolina Biotechnology Center has inaugurated a new grant program to help evaluate the likelihood of commercial success for life science inventions from universities and non-profit research organizations statewide.
  • Durham drug development company Vascular BioSciences (VBS) has hit the big-time, chosen as one of this year’s two most highly innovative biotechnology companies.
  • The North Carolina Biotechnology Center awarded 33 loans and grants totaling $2,422,130 to companies, universities and other organizations across the state during the 2014-2015 fiscal year third quarter, which ended March 31.
  • Zen-Bio, a Research Triangle Park biotechnology and contract research firm, has landed another in a string of National Institutes of Health grants – this one for $224,000 to help in the global fight against obesity.
  • A potential new topical therapy for the treatment of acute migraine appears safe and effective, according to data that Achelios Therapeutics of Chapel Hill has prepared for presentation at an April 22 neurology conference.
  • Durham drug developer Innocrin Pharmaceuticals has closed on $28 million in Series D financing to test a new therapy for difficult prostate and breast cancers.
  • Eisai, the Tokyo-based global biopharmaceutical company, said only a “handful” of the company’s 200-plus job cuts announced today would involve the company’s 190 employees in North Carolina.

Pages

Subscribe to News & Events